Skip to main
AVDL

Avadel Pharma (AVDL) Stock Forecast & Price Target

Avadel Pharma (AVDL) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 29%
Buy 0%
Hold 71%
Sell 0%
Strong Sell 0%

Bulls say

Avadel Pharmaceuticals PLC is positioned for significant growth through its flagship product, LUMRYZ, which could achieve over $500 million in peak sales due to its convenient once-nightly dosing compared to existing sodium oxybate treatments. The company has recently reached cash flow positivity, fueled by the robust sales growth of LUMRYZ since its approval in 2023, and has established a strong patient base that is showing an increasing preference for this product. Moreover, Avadel's strategic transaction terms and ongoing pivotal trials in indications like idiopathic hypersomnia further enhance its potential for expansion and financial success in the pharmaceutical market.

Bears say

Avadel Pharmaceuticals faces significant risks that contribute to a negative outlook on its stock, particularly regarding its flagship product, LUMRYZ. Key concerns include the potential for slower market uptake due to impending generic competition, which may lead to greater pricing pressures and hinder sales projections. Additionally, the company's prospects are further complicated by litigation risks, challenges in demonstrating the efficacy of LUMRYZ in ongoing clinical trials, and possible delays in commercialization efforts for new indications.

Avadel Pharma (AVDL) has been analyzed by 7 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 0% recommend Buy, 71% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Avadel Pharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Avadel Pharma (AVDL) Forecast

Analysts have given Avadel Pharma (AVDL) a Buy based on their latest research and market trends.

According to 7 analysts, Avadel Pharma (AVDL) has a Buy consensus rating as of Jan 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Avadel Pharma (AVDL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.